Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer.

Angevin, E; Valteau-Couanet, D; Farace, F; Dietrich, P Y; Lecesne, A; Triebel, F; Escudier, B

Angevin, E; Valteau-Couanet, D; Farace, F; Dietrich, P Y; Lecesne, A; Triebel, F; Escudier, B.

Affiliation

Angevin E; Unité d'Immunothérapie, Institut Gustave Roussy, Villejuif, France.

J Immunother Emphasis Tumor Immunol ; 18(3): 188-95, 1995 Oct.

Article in En | MEDLINE | ID: mdl-8770775

Subject(s)

Interleukin-2/administration & dosage; Neoplasms/therapy; Adult; Aged; Carcinoma, Renal Cell/secondary; Carcinoma, Renal Cell/therapy; Drug Tolerance; Eosinophilia/etiology; Female; Humans; Immunotherapy; Injections, Subcutaneous; Interleukin-2/adverse effects; Kidney Neoplasms/therapy; Lymphocytosis/etiology; Male; Middle Aged; Recombinant Proteins/administration & dosage; Recombinant Proteins/adverse effects; Safety; Time Factors

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Interleukin-2 / Neoplasms Type of study: Clinical_trials / Etiology_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Immunother Emphasis Tumor Immunol Journal subject: ALERGIA E IMUNOLOGIA / FARMACOLOGIA / NEOPLASIAS Year: 1995 Document type: Article Affiliation country: France

Search on Google

Add to My VHL

XML

PubMed Links